What a high-performing biotech content calendar actually looks like

Most biotech content calendars are a shared spreadsheet, a Slack channel where someone posts "reminder to post this week," and a list of upcoming conferences nobody has written anything about yet. That is a 4 out of 10.

A 10 out of 10 is a calendar that connects every piece of content to a strategic objective, runs through a defined review process, and produces consistent output regardless of whether a key person is travelling or heads-down on a submission. It is operated by a team of two or three people and does not require a full-time content manager to function.

This post defines what the 10 out of 10 actually requires — and gives you a way to score yourself honestly against it.

Why most biotech content calendars fall short

The failure mode is almost always the same: the calendar reflects activity rather than strategy.

A team decides to post on LinkedIn three times a week. They fill the calendar with whatever feels timely — a conference announcement here, a congratulations post there, a repost of a journal article. Output is inconsistent. Engagement is low. The calendar gets abandoned in Q2 and revived in Q3 when someone asks why the company has been quiet.

There are three structural reasons this happens in life sciences that don't apply in other industries.

Review cycles are genuinely long

In a 20-person biotech, a LinkedIn post may need sign-off from the CEO, CMO, and sometimes legal or regulatory affairs before it goes live. According to a 2024 survey by Biopharm Communications, the average content approval cycle at pre-commercial life sciences companies is 6.4 days. A team planning to post three times a week cannot function if posts are approved on a rolling, ad-hoc basis.

Content is tied to science that the marketing team doesn't fully own

A publication, a data readout, or a conference presentation can shift what needs to be communicated on a 48-hour timeline. A content calendar that can't flex around scientific events will break every quarter.

Therapeutic area specificity is non-negotiable

A content calendar that treats "oncology" and "rare disease" as interchangeable is not a life sciences content calendar. The KOLs, conferences, publications, and BD audiences are entirely different. A calendar built without therapeutic area anchoring will produce content that reaches no specific audience well.

High-performing teams solve all three of these before they build the calendar itself.

The framework: what a high-performing biotech content calendar actually requires

This framework has five components. Most teams have one or two. Teams operating at a high level have all five working in coordination.

1. Strategic anchors, not topic lists

A content calendar starts with three to five strategic anchors — the specific things the company needs to be known for over the next six to twelve months. Not "our pipeline." Not "our science." Specific, defensible positions.

For a pre-commercial oncology company ahead of a Phase 2 readout: the strategic anchors might be (1) the unmet need in a specific tumour type, (2) a differentiated mechanism of action, and (3) the team's clinical development expertise. Everything on the calendar maps to one of those three anchors. Posts that don't map to an anchor don't go on the calendar.

This is how high-performing teams avoid the "what do we post this week" problem. The question is never "what should we say?" It is "which anchor does this moment serve, and what is the best format to serve it?"

What this looks like in practice:

2. A publishing rhythm that accounts for approval time

The calendar is built backwards from the publish date, not forwards from the drafting date.

If approval takes an average of five business days, a post going live on Thursday needs to be in review by the previous Friday. The calendar shows both dates — draft-complete and publish — not just the publish date. A team that only tracks publish dates will consistently miss them.

High-performing teams set a fixed review rhythm: a defined window each week when all pending posts are reviewed, a defined escalation path when a reviewer is unavailable, and a backlog of approved evergreen posts that can fill gaps without triggering a new review cycle.

The publishing rhythm itself should match the team's realistic sustainable capacity, not an aspirational number. A team of two that publishes three LinkedIn posts per week consistently for twelve months outperforms a team that publishes five per week for six weeks and then collapses. The goal is cadence over volume.

3. A review architecture with defined roles

Every post needs exactly one approver and a defined deadline for that approval. Not "the CEO reviews things" — the CEO reviews posts in this category, the CMO reviews posts in this category, and regulatory review is required for posts that make any product-related claim.

The four roles that need to be defined before the calendar functions:

• Author — drafts the post; may be a marketer, a ghostwriter for a founder, or an external agency

• Scientific reviewer — checks factual accuracy; typically the CSO or a senior scientist; required for any post referencing clinical or preclinical data

• Commercial reviewer — checks strategic alignment and messaging; typically the CMO or CCO

• Final approver — gives the green light; typically the CEO for small teams, the CMO once a dedicated function exists

Posts that skip the scientific review step are the ones that generate corrections, deletions, or regulatory risk. The calendar should make scientific review the default, not the exception.

4. Conference integration built into the structure

The conference calendar is not a separate document. It is baked into the content calendar, with pre-event, during-event, and post-event slots pre-assigned twelve to sixteen weeks in advance.

For each conference the team attends or monitors, the calendar should contain:

• 4–6 weeks before: Why the team is attending; what they're presenting or what they're watching for

• 1 week before: Agenda highlights; who to meet if you're in the room

• During: Live updates from sessions, one-to-one meeting highlights (without disclosing confidential conversations), reaction to key data presented

• 1–2 weeks after: Synthesis post — what the conference told us about the field, the competitive landscape, or the unmet need; what it means for the company's position

Most biotech teams do the during-event posts and skip everything else. The before and after content is where the strategic value lives — and where the BD and investor audience who couldn't attend is paying attention.

For a deeper look at which Nordic and European conferences are worth building this structure around, the Pyroplane guide to the 6 conferences worth attending before your Series B covers the ones that move the needle for pre-Series B companies specifically.

5. Channel-specific formatting, not repurposed content

LinkedIn and the company blog are not interchangeable. High-performing teams treat them as distinct channels with distinct jobs.

The most common mistake is treating the blog as a place to publish LinkedIn posts that "need more room." A blog post is not a long LinkedIn post. It serves a fundamentally different audience with a fundamentally different need: someone who found the company through a search query and wants to know whether the company knows what it's talking about.

The calendar should have separate rows or sections for each channel, with content planned independently.

How to Evaluate Your Current Calendar Against This Framework

Score your current setup honestly against each component: 2 points if it is fully in place, 1 point if it exists in partial form, 0 if it doesn't exist.

8–10: High-performing. You have a system. 5–7: Functional but fragile. One person leaving or one busy quarter will break it. 0–4: Activity-based, not strategy-based. The calendar is a liability right now.

Most life sciences marketing teams score between 3 and 6 on their first honest pass. The most common gap is Component 1 — strategic anchors — because it requires a conversation with leadership that is easy to defer.

Common Implementation Mistakes

Building the calendar before defining the anchors

The calendar is an output of strategy, not a substitute for it. A team that jumps to "how many posts per week" before agreeing on what the company needs to be known for will produce a calendar full of activity and short on impact.

Treating the approval workflow as a process problem rather than a role problem

Adding more steps to the review process doesn't fix slow approvals. Assigning specific roles with specific deadlines does. If the CEO is the bottleneck, the solution is not a better submission form — it is a defined window each week when the CEO reviews posts, and a delegation path for when that window is missed.

Planning conference content reactively

The post-conference synthesis is the most read piece of conference content — and it is the one most teams never write because they're exhausted by the time the event ends. The fix is to block time in the calendar for the post-event write-up before the conference happens, not after.

Measuring output instead of reach

A team that tracks "posts published" without tracking who saw them cannot improve. LinkedIn analytics, at minimum, should show impressions, engagement rate, and follower growth on a monthly basis. Without that data, the calendar optimizes for effort rather than outcome.

For pre-commercial companies building this function from scratch, why pre-commercial biotech companies build their commercial presence 18 months too late covers the strategic case for starting earlier — and what "commercially visible" actually requires before you have a product to sell.

Conclusion

A content calendar that scores 9 or 10 against this framework is not a complex system. It is a simple system that has been defined clearly and maintained consistently. The teams that operate at that level are not the ones with the biggest budgets or the most marketers. They are the ones that made the upfront decisions — what we stand for, who reviews what, how far ahead we plan — and then built the calendar around those decisions rather than hoping the calendar would make the decisions for them.

The work of getting from a 4 to an 8 is almost entirely the work of the conversations you haven't had yet: with the CEO about what the company needs to be known for, with the scientific team about what is and isn't appropriate to publish, with the legal reviewer about what triggers a regulatory review. The calendar is the easy part.

Tools like Pyroplane are built around exactly this structure — approval workflows, conference integration, and channel-specific planning in one place — but the framework works regardless of what system you use to run it.

Sources:

• Biopharm Communications, Content Operations in Life Sciences Survey 2024 — industry survey of pre-commercial and commercial-stage biotech marketing teams

• LinkedIn Marketing Solutions, B2B Content Benchmark Report 2025 — business.linkedin.com

• IQVIA, The Changing Nature of Biotech Commercial Infrastructure 2025 — iqvia.com/insights